Related Experiment Videos
Bronchodilator therapy in chronic obstructive pulmonary disease
1Pulmonary Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Current Opinion in Pulmonary Medicine
|March 31, 2000
Summary
New bronchodilator therapies for chronic obstructive pulmonary disease (COPD) show promise. While combinations improve lung function, predicting patient response and managing beta-agonist side effects remain key challenges for optimal COPD treatment.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) management relies heavily on bronchodilator therapy.
- Predicting individual patient response to bronchodilators in COPD is currently unreliable.
Purpose of the Study:
- To review recent advancements in bronchodilator treatments for COPD.
- To discuss the efficacy and safety of different bronchodilator classes and combinations.
Main Methods:
- Literature review of new developments in bronchodilator therapy for COPD.
- Analysis of patient response assessment, considering lung volumes and FEV1.
- Evaluation of combination therapy versus monotherapy.
Main Results:
- Most COPD patients benefit from bronchodilators, but predictive markers are lacking.
- Combined beta-agonist and anticholinergic therapy offers superior improvement compared to single agents.
- Anticholinergic agents generally have a favorable side effect profile in COPD.
Conclusions:
- Assessing bronchodilator responsiveness should include lung volume changes alongside FEV1.
- Concerns persist regarding potential cardiac side effects of beta-agonists.
- The role of long-acting beta-agonists versus anticholinergic agents as first-line COPD therapy requires further investigation.